• Zhihao Chen, Chaohui Jiang, Huimin Qu, Shuang Liang, Jian Yang, Hui Wu, Chao He, and Xinan Wang.
• Department of Cardiology, Xiang'an Hospital of Xiamen University, Xiamen, China.
• Arch Med Sci. 2019 Oct 1; 15 (6): 1375-1380.

IntroductionThe aim of the current study was to evaluate the association between lipoprotein(a) [Lp(a)] and major adverse cardiovascular events (MACEs) in patients with percutaneous coronary intervention (PCI) treatment.Material And MethodsThis was a retrospective study. The demographics, prior medical histories, comorbidities and laboratory parameters were collected from the electronic health record. All participants were followed up for 1 year after the indexed PCI. Studied end points were a composite of MACEs including all-cause mortality, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, transient ischemic attack and stent restenosis.ResultsDuring 1-year follow-up, 87 MACEs occurred. Compared to patients who did not have MACEs, patients who had MACEs were older, more likely to have higher body mass index, diabetes mellitus and left main lesion, and also had higher baseline low density lipoprotein cholesterol (LDL-C) and Lp(a) levels. All patients in both groups were prescribed aspirin and clopidogrel at discharge. Nearly 97.4% and 95.4% of patients in both groups were treated with statins and a higher proportion of patients in the MACE group were treated with ezetimibe (11.5% vs. 3.5%, p < 0.05). In multivariate regression analysis, diabetes mellitus, LDL-C, Lp(a) and glomerular filtration rate were independent risk factors for MACEs; statin use appeared to be a protective factor for MACEs. Patients with increased Lp(a) level had significantly higher incidence of MACEs than the normal Lp(a) level group (p = 0.001).ConclusionsBaseline serum Lp(a) can be used to predict MACEs in patients after PCI treatment, which was independent of LDL-C.Copyright: © 2018 Termedia & Banach.

3 keywords...

hide…